X0303 4 2009-11-03 0000310158 Merck & Co. Inc. MRK 0001475384 Bowles Richard S III ONE MERCK DRIVE WHITEHOUSE STATION NJ 08889-0100 1 Exe V-P & Chief Compl Officer Common Stock 2009-11-03 4 A 0 4014 0 A 83503 D Common Stock 2009-11-03 4 D 0 33648 0 D 49855 D Common Stock 2009-11-03 4 A 0 252 0 A 252 I As Custodian Common Stock - 401(k) Plan 2009-11-03 4 A 0 3377.3284 0 A 3377.3284 I By 401(k) Stock Option (right to buy) 54.25 2009-11-03 4 D 0 6139 0 D 2002-01-02 2011-01-01 Common Stock 6139 63861 D Stock Option (right to buy) 40.05 2009-11-03 4 D 0 1467 0 D 2002-02-26 2011-02-25 Common Stock 1467 16133 D Stock Option (right to buy) 34.68 2009-11-03 4 D 0 2132 0 D 2003-02-25 2012-02-24 Common Stock 2132 22168 D Stock Option (right to buy) 18.2 2009-11-03 4 D 0 5262 0 D 2005-02-23 2014-02-22 Common Stock 5262 54738 D Stock Option (right to buy) 20.7 2009-11-03 4 D 0 5262 0 D 2006-04-25 2015-04-24 Common Stock 5262 54738 D Stock Option (right to buy) 19.23 2009-11-03 4 D 0 4824 0 D 2007-05-19 2013-05-18 Common Stock 4824 50176 D Stock Option (right to buy) 31.57 2009-11-03 4 D 0 4385 0 D 2008-05-01 2014-04-30 Common Stock 4385 45615 D Stock Option (right to buy) 18.85 2009-11-03 4 D 0 2631 0 D 2009-05-01 2015-04-30 Common Stock 2631 27369 D Stock Option (right to buy) 22.91 2009-11-03 4 D 0 2702 0 D 2010-05-01 2016-04-30 Common Stock 2702 28098 D Pursuant to the Merger Agreement, each share of common stock of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) was converted to an equal number of shares of New Merck. Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement. Received as part of the Agreement and Plan of Merger by and among, inter alia, Merck Sharp & Dohme Corp. and Merck & Co., Inc. (formerly Schering-Plough Corporation) in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. common stock held under the Merck Sharp & Dohme Corp. 401(k) plan. The option price for the grant expiring 1/01/11 will convert from $54.25 to $59.47. The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions. Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 2/25/11 will convert from $40.05 to $43.90. The option price for the grant expiring 2/24/12 will convert from $34.68 to $38.01. The option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95. The option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69. The option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08. The option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60. The option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66. The option price for the grant expiring 4/30/16 will convert from $22.91 to 25.11. Debra A. Bollwage as Attorney-in-Fact for Richard S. Bowles, III 2009-11-06